SEC Form 4 · accession 0001209191-18-003012
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eldon C. Mayer III
Director
Period of report
Jan 5, 2018
Accepted (ET)
Jan 9, 2018 · 6:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.70 | Jan 5, 2018 | A | 25,000 | A | — | Jan 4, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option vests in equal monthly installments over 36 months measured from January 5, 2018, subject to Reporting Person's continuous service status as of each such date.